Skip to main content

Auto-antibodies to p53 and the Subsequent Development of Colorectal Cancer in a U.S. Prospective Cohort Consortium.

Publication ,  Journal Article
Butt, J; Blot, WJ; Visvanathan, K; Le Marchand, L; Wilkens, LR; Chen, Y; Sesso, HD; Teras, L; Ryser, MD; Hyslop, T; Wassertheil-Smoller, S ...
Published in: Cancer Epidemiol Biomarkers Prev
December 2020

BACKGROUND: Auto-antibodies to tumor suppressor p53 are found in a subset of patients with colorectal cancer. A recent prospective study in the United States has reported a significant 1.8-fold increased odds for colorectal cancer development with prediagnostic seropositivity to p53. In this study, we sought to examine this association in a U.S. colorectal cancer cohort consortium to evaluate the potential utility of p53 auto-antibodies as an early biomarker for colorectal cancer. METHODS: Auto-antibodies to p53 were measured in prediagnostic blood samples of 3,702 incident colorectal cancer cases and 3,702 controls, matched by age, race, and sex, from 9 U.S. prospective cohorts. The association of seropositivity to p53 with colorectal cancer risk, overall and by time between blood draw and diagnosis, was determined by conditional logistic regression. RESULTS: Overall, 5% of controls and 7% of cases were seropositive to p53, resulting in a statistically significant 33% increased colorectal cancer risk [odds ratio (OR), 1.33; 95% confidence interval (CI), 1.09-1.61]. By follow-up time, the association was only significant with colorectal cancer diagnoses within 4 years after blood draw (OR, 2.27; 95% CI, 1.62-3.19), but not thereafter (OR, 0.97; 95% CI, 0.76-1.24). CONCLUSIONS: In this large consortium of prospective cohorts, we found that prediagnostic seropositivity to tumor suppressor p53 was significantly associated with an over 2-fold increased odds of developing colorectal cancer within 4 years after blood draw. IMPACT: Our finding suggests that p53 seropositivity may not be a useful predictor of long-term colorectal cancer risk; however, it might be considered as a marker to aid in the early diagnosis of colorectal cancer.

Duke Scholars

Published In

Cancer Epidemiol Biomarkers Prev

DOI

EISSN

1538-7755

Publication Date

December 2020

Volume

29

Issue

12

Start / End Page

2729 / 2734

Location

United States

Related Subject Headings

  • United States
  • Tumor Suppressor Protein p53
  • Prospective Studies
  • Male
  • Humans
  • Female
  • Epidemiology
  • Colorectal Neoplasms
  • Cohort Studies
  • Autoantibodies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Butt, J., Blot, W. J., Visvanathan, K., Le Marchand, L., Wilkens, L. R., Chen, Y., … Epplein, M. (2020). Auto-antibodies to p53 and the Subsequent Development of Colorectal Cancer in a U.S. Prospective Cohort Consortium. Cancer Epidemiol Biomarkers Prev, 29(12), 2729–2734. https://doi.org/10.1158/1055-9965.EPI-20-0780
Butt, Julia, William J. Blot, Kala Visvanathan, Loïc Le Marchand, Lynne R. Wilkens, Yu Chen, Howard D. Sesso, et al. “Auto-antibodies to p53 and the Subsequent Development of Colorectal Cancer in a U.S. Prospective Cohort Consortium.Cancer Epidemiol Biomarkers Prev 29, no. 12 (December 2020): 2729–34. https://doi.org/10.1158/1055-9965.EPI-20-0780.
Butt J, Blot WJ, Visvanathan K, Le Marchand L, Wilkens LR, Chen Y, et al. Auto-antibodies to p53 and the Subsequent Development of Colorectal Cancer in a U.S. Prospective Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2729–34.
Butt, Julia, et al. “Auto-antibodies to p53 and the Subsequent Development of Colorectal Cancer in a U.S. Prospective Cohort Consortium.Cancer Epidemiol Biomarkers Prev, vol. 29, no. 12, Dec. 2020, pp. 2729–34. Pubmed, doi:10.1158/1055-9965.EPI-20-0780.
Butt J, Blot WJ, Visvanathan K, Le Marchand L, Wilkens LR, Chen Y, Sesso HD, Teras L, Ryser MD, Hyslop T, Wassertheil-Smoller S, Tinker LF, Potter JD, Song M, Berndt SI, Waterboer T, Pawlita M, Epplein M. Auto-antibodies to p53 and the Subsequent Development of Colorectal Cancer in a U.S. Prospective Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2729–2734.

Published In

Cancer Epidemiol Biomarkers Prev

DOI

EISSN

1538-7755

Publication Date

December 2020

Volume

29

Issue

12

Start / End Page

2729 / 2734

Location

United States

Related Subject Headings

  • United States
  • Tumor Suppressor Protein p53
  • Prospective Studies
  • Male
  • Humans
  • Female
  • Epidemiology
  • Colorectal Neoplasms
  • Cohort Studies
  • Autoantibodies